
    
      The specific aims of this study are to:

        -  To evaluate the effects of liraglutide on body weight loss in patients who are
           experiencing weight regain following RYGB.

        -  To evaluate the effects of liraglutide on cardiometabolic risk and quality of life in
           patients who are experiencing weight regain following RYGB.

        -  To evaluate the safety of liraglutide in post-RYGB subjects.

        -  To evaluate the changes in obesity-related comorbid conditions in patients who are
           experiencing weight regain following RYGB.
    
  